Jefferies & Company has downgraded Bristol-Myers Squibb BMY from Buy to Hold and maintains its $28.50.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: DowngradesPrice TargetAnalyst Ratingsbristol-myers squibbHealth CareJefferies & CompanyPharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
